Effect of Bevacizumab on Human Tenon's Fibroblasts Cultured from Primary and Recurrent Pterygium.
10.4196/kjpp.2015.19.4.357
- Author:
Young Min PARK
1
;
Chi Dae KIM
;
Jong Soo LEE
Author Information
1. Department of Ophthalmology, Pusan National University School of Medicine & Medical Research Institute, Yangsan Pusan National University Hospital, Yangsan 626-770, Korea.
- Publication Type:Original Article
- Keywords:
Anti-fibrotic effect;
Bevacizumab;
Extracellular matrix;
Human Tenon's fibroblasts;
Pterygium
- MeSH:
Collagen Type I;
Collagenases;
Extracellular Matrix;
Fibroblasts*;
Humans;
Immunoassay;
L-Lactate Dehydrogenase;
Laminin;
Metabolism;
Microscopy, Electron, Transmission;
Pterygium*;
Bevacizumab
- From:The Korean Journal of Physiology and Pharmacology
2015;19(4):357-363
- CountryRepublic of Korea
- Language:English
-
Abstract:
The purpose of this study was to compare the inhibitory effect of bevacizumab on human Tenon's fibroblasts (HTFs) cultured from primary and recurrent pterygium. Cultured HTFs were exposed to 2.0, 5.0, 7.5, and 15.0 mg/mL concentration of bevacizumab for 24 hours. The 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide and lactate dehydrogenase leakage assays were then performed to assess fibroblast metabolism and viability. The matrix metalloproteinase (MMP), procollagen type I C terminal propeptide (PIP), and laminin immunoassays were performed to examine extracellular matrix production. Changes in cellular morphology were examined by phase-contrast and transmission electron microscopy. Both metabolic activity and viability of primary and recurrent pterygium HTFs were inhibited by bevacizumab in a dose-dependent manner, especially at concentrations greater than 7.5 mg/mL. Both types of HTFs had significant decreases in MMP-1, PIP, and laminin levels. Distinctly, the inhibitory effect of bevacizumab on MMP-1 level related with collagenase in primary pterygium HTFs was significantly higher than that of recurrent pterygium. Significant changes in cellular density and morphology both occurred at bevacizumab concentrations greater than 7.5 mg/mL. Only primary pterygium HTFs had a reduction in cellular density at a bevacizumab concentration of 5.0 mg/mL. Bevacizumab inhibits primary and recurrent pterygium HTFs in a dose-dependent manner, especially at concentrations greater than 7.5 mg/mL. As the primary HTFs produces larger amounts of MMP-1 compared to recurrent HTFs, significant reduction in MMP-1 level in primary pterygium HTFs after exposure to bevacizumab is likely to be related to the faster cellular density changes in primary pterygium HTFs.
